Wall Street brokerages expect that Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) will report earnings per share of ($0.34) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Aurinia Pharmaceuticals’ earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.42). Aurinia Pharmaceuticals posted earnings per share of ($0.15) in the same quarter last year, which would indicate a negative year-over-year growth rate of 126.7%. The company is scheduled to report its next earnings report on Thursday, May 13th.
On average, analysts expect that Aurinia Pharmaceuticals will report full year earnings of ($1.09) per share for the current year, with EPS estimates ranging from ($1.35) to ($0.81). For the next financial year, analysts anticipate that the business will report earnings of ($0.21) per share, with EPS estimates ranging from ($0.70) to $0.24. Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Tuesday, February 23rd. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.26. Aurinia Pharmaceuticals had a negative return on equity of 36.98% and a negative net margin of 173,992.23%. The firm had revenue of $50.03 million for the quarter, compared to the consensus estimate of $0.06 million.
Several equities analysts recently weighed in on AUPH shares. Zacks Investment Research downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, February 18th. Cantor Fitzgerald raised their price objective on Aurinia Pharmaceuticals from $27.00 to $34.00 and gave the stock an “overweight” rating in a report on Tuesday, January 26th. Royal Bank of Canada cut their price objective on Aurinia Pharmaceuticals from $28.00 to $26.00 and set an “outperform” rating on the stock in a report on Thursday, February 25th. Oppenheimer raised their price objective on Aurinia Pharmaceuticals from $20.00 to $28.00 in a report on Monday, January 25th. Finally, HC Wainwright raised their price objective on Aurinia Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, January 25th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. Aurinia Pharmaceuticals presently has an average rating of “Buy” and an average target price of $26.71.
Several hedge funds have recently bought and sold shares of AUPH. Morgan Stanley grew its stake in shares of Aurinia Pharmaceuticals by 32.1% in the third quarter. Morgan Stanley now owns 124,824 shares of the biotechnology company’s stock valued at $1,839,000 after buying an additional 30,329 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Aurinia Pharmaceuticals during the 3rd quarter valued at approximately $1,357,000. Great West Life Assurance Co. Can grew its stake in Aurinia Pharmaceuticals by 6.2% during the 3rd quarter. Great West Life Assurance Co. Can now owns 12,682 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 739 shares in the last quarter. Chiron Capital Management LLC acquired a new stake in Aurinia Pharmaceuticals during the 3rd quarter valued at approximately $143,000. Finally, International Biotechnology Trust PLC acquired a new stake in Aurinia Pharmaceuticals during the 3rd quarter valued at approximately $1,694,000. Institutional investors and hedge funds own 51.21% of the company’s stock.
NASDAQ AUPH opened at $12.49 on Friday. The business’s 50-day moving average price is $12.97 and its 200 day moving average price is $14.30. Aurinia Pharmaceuticals has a twelve month low of $11.60 and a twelve month high of $20.50. The company has a market capitalization of $1.59 billion, a PE ratio of -8.50 and a beta of 0.87.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Recommended Story: Why does a company issue an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: LIBOR
By the time you read this Vladimir Tenev, the CEO of the trading app Robinhood, will be testifying in front of Congress. The company’s role in the GameStop (NYSE:GME) short squeeze will be called into question.
However, the real issue at stake is the right of traders to buy and sell the equities of their choice. In the case of Robinhood, some traders are buying a lot of penny stocks. While definitions vary, penny stocks are generally considered stocks that are trading for less than $10 per share. These stocks are largely ignored by the investment community.
One reason is that many of these stocks are cheap for a reason. For example, the company may have a business model that is out of date. In other cases, they operate in a very small, niche market that doesn’t drive a lot of revenue.
And most of these stocks are ignored by the investment community. They simply aren’t considered significant enough to spend time debating.
But some penny stocks do have the attention of Wall Street. And they’re being largely ignored by the day trading community. The focus of this special presentation is to direct you to penny stocks that have a story that the “smart money” thinks will eventually be trading at much higher prices.
And that’s why you should be looking at them now.